The world is once again hearing the name of a little-known antiviral drug that became globally famous during the COVID-19 pandemic.
As reported by Reuters, Britain, scrambling to stay one step ahead of the hantavirus outbreak linked to that ill-fated Antarctic cruise MV Hondius, has just brought in emergency supplies of this antiviral from Japan. It’s not a household name, but if you kept up with COVID headlines,
Favipiravir probably sounds vaguely familiar. It had a moment during the early pandemic before fading from view, and now, thanks to hantavirus, it’s back.
So what exactly is this drug? Why is the UK leaning on it, and what do we know about how well it works?
Let’s unpack all the details.
Favipiravir: What exactly is it?
Favipiravir has an odd history. It was developed in Japan by Toyama Chemical (now part of Fujifilm) and sold as Avigan. Japan approved it in 2014 for emergency use against new influenza strains. Unlike antibiotics, which work on bacteria, Favipiravir messes with the machinery certain viruses use to copy themselves (the RNA polymerase). That makes it a so-called “broad-spectrum” antiviral, best known for showing lab activity against a whole bunch of RNA viruses.
Governments keep an eye on drugs like this for those “just in case” situations.
Back in the early COVID days, Favipiravir was hyped in countries like India, Russia, and Japan. It was even given to mild and moderate COVID patients because it came as pills, so you didn’t need a hospital IV. Early hopes were that it’d help people recover faster or slow the virus down, but by late 2020, the research was messy. Small studies, mixed results. In the end, big reviews said Favipiravir doesn’t really lower death rates or stop severe disease. It’s not useless, but it’s no medical miracle either.
Now, hantavirus has given the drug another shot.
The real worry in the current outbreak is the Andes hantavirus strain, capable of that rare person-to-person spread. When the UK Health Security Agency realized some Brits could get severely ill, and with no approved drugs for hantavirus, they welcomed extra options. Over the weekend, Japan shipped supplies of Favipiravir as a “just in case” move. The drug isn’t officially licensed here for this use, but doctors could try it under compassionate or experimental protocols if someone’s seriously sick.
But why so?
Well, animal tests suggest Favipiravir might help against some hantaviruses, and a few scattered human reports add to the hope, but evidence is still thin. There’s no proven antiviral for hantavirus pulmonary syndrome (which can quickly turn deadly, with a 35-40% mortality rate when the Andes virus is involved). Treatment, right now, is all about supportive care: oxygen, fluids, plenty of hospital monitoring.
Those risks are why Britain moved fast on the import, but Favipiravir isn’t risk-free. Studies have linked it to birth defects in animals, so it’s a no-go in pregnancy. Doctors also have to keep an eye on possible liver problems, gout, and stomach upset.
The larger context is that the world has changed since COVID. Governments are more willing to stockpile experimental antivirals, act quickly, and partner across borders. That’s why Japan’s supply arrived so fast. These emergency responses are now standard fare.
For the common people, none of this spells a pandemic, at least not right now. The WHO keeps insisting the risk outside those exposed is very low. The Andes virus still hasn’t become easier to catch, and Europe doesn’t have the right rodents, anyway.
Still, the fact that Favipiravir might be back in use is a telling reality of the post-pandemic world: a forgotten cruise, a rare virus, a repurposed COVID drug, and a scramble for life-saving options that nobody saw coming.
Sure, the WHO assures that the ongoing hantavirus outbreak isn’t the same as the COVID-19 pandemic, but somehow, here we are — back to using a drug that had its first international moment during COVID is back in the spotlight.
Follow Us On Social Media